A5049011740- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Breast Cancer Treatment Studies
- Cancer Research and Treatments
- Virus-based gene therapy research
- Estrogen and related hormone effects
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Mathematical Biology Tumor Growth
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Management of metastatic bone disease
- Autoimmune Neurological Disorders and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
Houston Methodist
2017-2024
Methodist Hospital
2017-2024
Baylor College of Medicine
2013-2022
University Prep
2021
Cornell University
2017-2021
Weill Cornell Medicine
2017-2021
Ibero American University
2018
Methodist Hospital
2018
Novartis (Canada)
2018
Dana-Farber Brigham Cancer Center
2016
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer to the CNS are limited. We previously reported modest activity of neratinib monotherapy HER2-positive brain metastases. Here we report results from additional study cohorts.Patients with measurable, progressive, metastases (92% after receiving surgery and/or radiotherapy) received 240 mg orally once per day plus capecitabine 750 mg/m2 twice 14 days, then 7 days off....
<h3>Importance</h3> Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not assessed in a randomized clinical trial. <h3>Objectives</h3> To assess whether device is effective at reducing chemotherapy-induced alopecia and adverse treatment effects. <h3>Design, Setting, Participants</h3> Multicenter trial of women with breast cancer undergoing chemotherapy. Patients were enrolled from December 9, 2013, September 30, 2016. One...
Abstract Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response (CR/PR) or stable disease (SD) ≥24 weeks, in HER2mut nonamplified metastatic breast cancer (MBC). Secondary endpoints included progression-free survival (PFS), toxicity, and circulating tumor DNA (ctDNA) detection. Experimental Design: Tumor tissue positive for was required eligibility. Neratinib...
Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity HER2-positive cancer; however, its unknown. We evaluated efficacy treatment neratinib patients brain metastases a multicenter, phase II open-label trial.Eligible were those (≥ 1 cm longest dimension) who experienced progression after one or more line CNS-directed...
A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.
Abstract Purpose: Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate pCR. Patients and Methods: TBCRC023 (NCT00999804) is randomized phase II trial combining Simon design experimental arm pick-the-winner design, not powered for direct comparison. Women tumors measuring ≥2...
Abstract Purpose: A Phase 2 trial of stereotactic radiotherapy and in situ cytotoxic virus therapy patients with metastatic triple-negative breast cancer (mTNBC) followed by pembrolizumab (STOMP) was designed to evaluate dual approach enhancing single-agent immune checkpoint blockade adenovirus-mediated expression herpes-simplex-virus thymidine-kinase (ADV/HSV-tk) plus valacyclovir gene body (SBRT) mTNBC. Patients Methods: In this single-arm, open-label trial, mTNBC were treated ADV/HSV-tk...
Metaplastic breast cancer (MBC) is a rare, aggressive variant of that has been associated with poor clinical outcomes, as triple-negative (TNBC) cancer. Limited studies compare the characteristics and prognosis MBC to TNBC. This study uses large, contemporary US database survival outcomes for patients those TNBC.The National Cancer Database was queried women cT1-4N1-3M0 or TNBC diagnosed between 2004 2013 treated definitive surgery. Chi-squared analysis performed determine differences...
1005 Background: Evidence-based treatments (tx) for metastatic, HER2+ BCBM are limited. We previously found a central nervous system (CNS) objective response rate (ORR) of 8% (95% CI 2-22%) the irreversible, EGFR/HER2-targeted kinase inhibitor, neratinib. To enhance CNS activity, we evaluated combination neratinib + capecitabine in subsequent cohort, and report results here. Methods: Pts with measurable (≥ 1 cm longest dimension) no prior lapatinib or were eligible. All but 3 had progression...
Abstract Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the major mechanisms resistance. We designed an open-label phase II clinical trial to evaluate if combination everolimus (mTOR inhibitor) cisplatin (interferes with function) will improve rate response, as assessed by residual burden (RCB). Twenty-four Stage II/III TNBC > 1...
Only 34% of breast cancer survivors engage in the recommended level physical activity because a lack accountability and motivation. Methodist Hospital Cancer Health Application (MOCHA) is smartphone tool created specifically for self-reinforcement patients with through daily accounting nutrition direct interaction clinical dietitians. We hypothesize that use MOCHA will improve help them reach their personalized goals.Women stages I to III who were at least 6 months post-active treatment body...
Abstract Background: We have previously shown in animal models that combination anti-HER2 therapy leads to complete tumor regression of HER2+ breast cancer (BC). translated these findings a neoadjuvant trial 12 weeks (wks) L+T (TBCRC006) demonstrated meaningful pathologic response (pCR) and near pCR (in ER+ tumors) patients with locally advanced BC. In the present trial, we sought determine whether longer treatment would lead higher rate without use chemotherapy by converting especially...
516 Background: HER2 mutation occurs in ~2% of breast cancer (BC). Preclinical models suggested neratinib, an irreversible HER2/EGFR tyrosine kinase inhibitor, could be effective treatment. This trial was conducted to assess the clinical benefit rate (CBR), defined as complete response (CR), partial (PR) or stable disease (SD) ≥ 6 months (mo.), for neratinib patients (pts) with HER2mutMBC (NCT01670877). Methods: single arm phase II employed Simon's Optimal 2-stage design (1st stage: n=10,...
Abstract Purpose This study evaluated the proportion of premenopausal women who experience persistent ovarian escape (OE) while receiving suppression (OS) therapy for estrogen receptor-positive (ER+) breast cancer treatment. The also examined clinical factors that may predispose to higher risk OE. Materials and Methods was a retrospective, “real-world” evaluate adjuvant endocrine OS therapy. primary objective measure percentage OE within first 3 months injections (using either leuprolide or...
Abstract Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a very common dose-limiting side effect of many cancer treatments. However, the optimal treatment for CIPN remains unclear. Electroacupuncture (EA) non-pharmacologic that combines traditional acupuncture with electrical stimulation. EA being examined and has shown modest benefits. Design: This pilot, single-center, prospective, single-arm, non-blinded study. All subjects had residual grade ≥2 after having received...
Breast cancer liver metastases (BCLM) are hypovascular lesions that resist intravenously administered therapies and have grim prognosis. Immunotherapeutic strategies targeting BCLM critically depend on the tumor microenvironment (TME), including tumor-associated macrophages. However, a priori characterization of TME to optimize therapy is challenging because tissue rarely collected. In contrast primary breast tumors for which usually obtained histologic analysis performed, biopsies or...